Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple]dose study in healthy subjects

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1131-1138

  Sidharta, Patricia N ^a   Van Giersbergen, Paul L M ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Endothelin receptor antagonist; Healthy subjects; Macitentan; Pharmacodynamics; Pharmacokinetics

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ACT 132577; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE SALT; BILIRUBIN; CYTOCHROME P450 3A4; DRUG METABOLITE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROCORTISONE; MACITENTAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRED VISION; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FOLLICULITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; LACERATION; LIVER FUNCTION TEST; MALE; MIDDLE AGED; MYALGIA; NORMAL HUMAN; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; THIRST; UPPER ABDOMINAL PAIN; URINARY EXCRETION; YOUNG ADULT;

ENDOTHELIN RECEPTOR ANTAGONIST; HEALTHY SUBJECTS; MACITENTAN; PHARMACODYNAMICS; PHARMACOKINETICS;

ADULT; BILE ACIDS AND SALTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIN-1; HUMANS; HYDROCORTISONE; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; YOUNG ADULT;

EID: 84892915544     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.152     Document Type: Article

References (35)

1. Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: The future1 study. J Clin Pharmacol. 2009;68(6):948-955.
2. Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: Great expectations or bleak house Br J Pharmacol. 2008;153(6):1105-1119.
3. Lalich M, McNeel DG, Wilding G, et al. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007;25(8):785-794.
4. Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev. 2010;18(3):148-162.
5. Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: Rationale and place in therapy. Am J Cardiovasc Drugs. 2008;8(3):171-185.
6. Dhillon S. Bosentan: A review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs. 2009;69(14): 2005-2024.
7. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Ann Intern Med. 2013;158(9):641-649.
8. Knobloch J, Lin Y, Konradi J, et al. Inflammatory responses of airway smooth muscle cells and effects of endothelin receptor antagonism. Am J Respir Cell Mol Biol. 2013;49(1):114-127.
9. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110(3):386-414.
10. Cross DM, Horsley E, Derzi M, et al. An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats. Birth Defects Res B Dev Reprod Toxicol. 2012;95(5):327-336.
11. Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012;110(9):1373-1377.
12. Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012;91(13-14):517-521.
13. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43(15):1089-1115.
14. Green RM, Hoda F, Ward KL. Molecular cloning and characterization of the murine bile salt export pump. Gene. 2000;241(1):117-123.
15. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69(4):223-231.
16. Bolli MH, Boss C, Binkert C, et al. The discovery of N[5(4 bromophenyl)6[2[(5bromo2pyrimidinyl)oxy]ethoxy]4pyrimidinyl] N0 propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55(17): 7849-7861.
17. Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE. 2012;7(10):e47662.
18. Iglarz M, Landskroner K, Rey M, et al. Macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension (abstract). Am J Respir Crit Care Med. 2011;183:A6445.
19. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissuetargeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736-745.
20. Sidharta PN, van Giersbergen PL, Halabi A, et al. Macitentan: Entryinto humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011;67(10):977-984.
21. Humbert M, Segal ES, Kiely DG, et al. Results of european postmarketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30(2):338-344.
22. GalteauMM, Shamsa F. Urinary 6bhydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through cyp3a in humans and animals. Eur J Clin Pharmacol. 2003;59: 713-733.
23. Kummer O, Haschke M, Hammann F, et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci. 2009;38(4):384-388.
24. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics uk joint working party. Drug Inf J. 1995;29:1039-1048.
25. Bruderer S, Aanismaa P, Homery MC, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissuetargeting dual endothelin receptor antagonist. AAPS J. 2012; 14(1):68-78.
26. Rubin LJ, Pulido T, Channick R, et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): Results from the seraphin trial. Am Coll Chest Physicians - Chest. 2012;142(4-meeting abstracts):1026A.
27. Sidharta PN, van Giersbergen PL, Wolzt M, et al. Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects. Am J Respir Crit Care Med. 2012;185:A4802.
28. Raghu G, MillionRousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial. Eur Respir J. 2013, doi: 10.1183/09031936.00104612
29. Rosenzweig P, Miget N, Brohier S. Transaminase elevation on placebo during phase I trials: Prevalence and significance. Br J Clin Pharmacol. 1999;48(1):19-23.
30. Hartman JC, Brouwer K, Mandagere A, et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwichcultured human hepatocytes. Can J Physiol Pharmacol. 2010;88(6):682-691.
31. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199(3):1461-1465.
32. Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013;52(8):685-692.
33. Weber C, Schmitt R, Birnboeck H, et al. Multipledose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol. 1999;39 (7):703-714.
34. Tran JQ, Kovacs SJ, McIntosh TS, et al. Morning spot and 24hour urinary 6 betahydroxycortisol to cortisol ratios: Intraindividual variability and correlation under basal conditions and conditions of cyp 3a4 induction. J Clin Pharmacol. 1999;39(5):487-494.
35. Liu YT, Hao HP, Liu CX, et al. Drugs as cyp3a probes, inducers, and inhibitors. Drug Metab Rev. 2007;39(4):699-721.